CA2443897A1 - Transporteurs et canaux ioniques - Google Patents

Transporteurs et canaux ioniques Download PDF

Info

Publication number
CA2443897A1
CA2443897A1 CA002443897A CA2443897A CA2443897A1 CA 2443897 A1 CA2443897 A1 CA 2443897A1 CA 002443897 A CA002443897 A CA 002443897A CA 2443897 A CA2443897 A CA 2443897A CA 2443897 A1 CA2443897 A1 CA 2443897A1
Authority
CA
Canada
Prior art keywords
polynucleotide
polypeptide
seq
amino acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002443897A
Other languages
English (en)
Inventor
Mariah R. Baughn
Vicki S. Elliott
April J. A. Hafalia
Junming Yang
Narinder K. Chawla
Jayalaxmi Ramkumar
Ian J. Forsythe
Yan Lu
Y. Tom Tang
Henry Yue
Brigitte E. Raumann
Preeti G. Lal
Yalda Azimzai
Dyung Aina M. Lu
Ameena R. Gandhi
Michael Thornton
Danniel B. Nguyen
Chandra S. Arvizu
Brooke M. Emerling
Anita Swarnakar
Monique G. Yao
Li Ding
Ann He
Jennifer A. Griffin
Madhu M. Sanjanwala
Kimberly J. Gietzen
Ernestine A. Lee
Yuming Xu
Janice K. Au-Young
Debopriya Das
Soo Yeun Lee
Hsin-Ru Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Incyte Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc filed Critical Incyte Genomics Inc
Publication of CA2443897A1 publication Critical patent/CA2443897A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

L'invention concerne des transporteurs humains et des canaux ioniques (TRICH) ainsi que des polynucléotides qui les identifient et les codent. L'invention concerne également des vecteurs d'expression, des cellules hôtes, des anticorps, des agonistes et des antagonistes. Elle concerne enfin des procédés de diagnostic, de traitement ou de prévention de troubles liés l'expression aberrante de TRICH.
CA002443897A 2001-04-12 2002-04-12 Transporteurs et canaux ioniques Abandoned CA2443897A1 (fr)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US28344001P 2001-04-12 2001-04-12
US60/283,440 2001-04-12
US28559201P 2001-04-20 2001-04-20
US60/285,592 2001-04-20
US28726301P 2001-04-27 2001-04-27
US60/287,263 2001-04-27
US28866601P 2001-05-04 2001-05-04
US60/288,666 2001-05-04
US29204201P 2001-05-18 2001-05-18
US60/292,042 2001-05-18
US29372401P 2001-05-25 2001-05-25
US60/293,724 2001-05-25
US35110702P 2002-01-22 2002-01-22
US60/351,107 2002-01-22
PCT/US2002/011760 WO2002083712A2 (fr) 2001-04-12 2002-04-12 Transporteurs et canaux ioniques

Publications (1)

Publication Number Publication Date
CA2443897A1 true CA2443897A1 (fr) 2002-10-24

Family

ID=27569579

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002443897A Abandoned CA2443897A1 (fr) 2001-04-12 2002-04-12 Transporteurs et canaux ioniques

Country Status (5)

Country Link
EP (1) EP1383798A4 (fr)
JP (1) JP2004533233A (fr)
AU (1) AU2002256215A1 (fr)
CA (1) CA2443897A1 (fr)
WO (1) WO2002083712A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002316150A1 (en) 2001-05-22 2002-12-03 Bristol-Myers Squibb Company Polynucleotide encoding a novel trp channel family member, trp-plik2, and splice variants thereof
WO2002097095A1 (fr) * 2001-05-25 2002-12-05 Lexicon Genetics Incorporated Nouvelles proteines transporteuses humaines et polynucleotides les codant
WO2003050300A2 (fr) * 2001-12-08 2003-06-19 The Victoria University Of Manchester Diagnostic et traitement du cancer
AU2003236041A1 (en) * 2002-04-12 2003-10-27 Takeda Chemical Industries, Ltd. Novel protein and dna thereof
WO2005040818A2 (fr) * 2003-10-17 2005-05-06 Bayer Healthcare Ag Diagnostics et traitements de maladies associees a un transporteur de cation organique flipt1 (flipt1)
US8119601B2 (en) 2005-03-10 2012-02-21 Ben-Gurion University Of The Negev Research And Development Authority Ltd. Voltage dependent anion channel (VDAC1) compositions and methods of use thereof for regulating apoptosis
US8648045B2 (en) 2005-03-10 2014-02-11 Ben Gurion University Of The Negev Research And Development Authority Ltd. VDAC1 compositions and methods of use thereof for regulating apoptosis
JP5757647B2 (ja) * 2010-02-19 2015-07-29 国立大学法人愛媛大学 高血圧のｓｎｐマーカー、高血圧発症リスク判定方法、及び、高血圧感受性遺伝子欠損小動物の使用方法
EP3024844B1 (fr) 2013-07-25 2018-09-12 The National Institute for Biotechnology in the Negev Ltd. Peptides courts dérivés de vdac1, compositions et procédés d'utilisation de ces peptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4424577A1 (de) * 1994-07-13 1996-01-18 Hoechst Ag Transportprotein, das den Transport von kationischen Xenobiotika und/oder Pharmaka bewirkt, dafür kodierende DNA-Sequenzen und deren Verwendung

Also Published As

Publication number Publication date
WO2002083712A3 (fr) 2003-05-01
AU2002256215A1 (en) 2002-10-28
WO2002083712A2 (fr) 2002-10-24
WO2002083712A8 (fr) 2002-11-28
JP2004533233A (ja) 2004-11-04
EP1383798A2 (fr) 2004-01-28
EP1383798A4 (fr) 2005-01-12

Similar Documents

Publication Publication Date Title
WO2002004520A2 (fr) Transporteurs et canaux ioniques
WO2001046258A2 (fr) Transporteurs et canaux ioniques
EP1320600A1 (fr) Tranporteurs et canneaux d'ion
WO2002046415A2 (fr) Transporteurs et canaux ioniques
WO2002040541A2 (fr) Transporteurs et canaux a ions
US20060194275A1 (en) Transporter and ion channels
EP1326972A2 (fr) Caneaux a ions et transporteurs
WO2001092304A2 (fr) Transporteurs et canaux ioniques
US20060035315A1 (en) Transporters and ion channels
CA2443897A1 (fr) Transporteurs et canaux ioniques
EP1381626A2 (fr) Transporteurs humains et canaux ioniques
CA2438206A1 (fr) Transporteurs et canaux ioniques
WO2003083085A2 (fr) Canaux ioniques et transporteurs
CA2413128A1 (fr) Transporteurs et canaux ioniques
US20030216310A1 (en) Transporters and ion channels
WO2004048599A2 (fr) Transporteurs et canaux ioniques
US20040014945A1 (en) Transporters and ion channels
US20040127683A1 (en) Transporters and ion channels
CA2447662A1 (fr) Transporteurs et canaux ioniques
US20040152874A1 (en) Transporter and ion channels
WO2004035755A2 (fr) Transporteurs et canaux ioniques
CA2422497A1 (fr) Transporteurs et canaux ioniques
WO2004083395A2 (fr) Transporteurs et canaux ioniques

Legal Events

Date Code Title Description
FZDE Dead